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Modulation of B Lymphocyte Antigen Receptor
Signal Transduction
by a CD19/CD22 Regulatory Loop
or CD19 ligation. CD19 regulates BCR signaling by am-
plifying Src-family protein tyrosine kinase (PTK) activa-
tion and mediating interactions between these PTKs
and downstream effector molecules, including phos-
phatidylinositol-3 (PI-3) kinase and Vav (Chalupny et al.,
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1993; Tuveson et al., 1993; Uckun et al., 1993; Weng etDurham, North Carolina 27710
al., 1994; Li et al., 1997; Sato et al., 1997a; O'Rourke et
al., 1998; Fujimoto et al., 1999). In the absence of CD19
expression, B cells from gene-targeted mice are hypore-Summary
sponsive to transmembrane signals and generate mod-
est immune responses (Engel et al., 1995; Rickert et al.,CD19 and CD22 are B lymphocyte cell-surface mole-
1995). Uniquely, small increases in CD19 expressioncules that positively and negatively regulate antigen
levels (20%±300%) in transgenic mice dramatically en-receptor signal transduction, respectively. Biochemi-
hance B cell responses to transmembrane signals andcal studies with B cells from CD19-deficient and CD22-
predispose these mice to autoimmunity (Zhou et al.,deficient mice indicated that these two regulatory
1994; Sato et al., 1995, 1996b, 1997b). These observa-molecules influenced each other's functions: CD22 ex-
tions suggest that CD19 expression and function arepression negatively regulated CD19 tyrosine phos-
tightly regulated under normal circumstances.phorylation, while optimal CD22 function was depen-
CD22 is a 140,000 Mr member of the Ig superfamilydent on CD19 expression. Functional CD19 and CD22
expressed in the cytoplasm of pro-B and pre-B cells
interactions were also assessed in vivo by generating
and on the cell surface as B cells mature to become
CD19/CD22 double-deficient mice. Remarkably, the
IgD-positive (reviewed in Tedder et al., 1997b). CD22
CD19 mutation was dominant to the CD22 mutation
is an adhesion receptor for sialic acid±bearing ligands
in most instances. B lymphocytes from CD19/CD22-
expressed in serum, and on disparate hematopoietic
deficient and CD19-deficient mice were functionally and nonhematopoietic cells (Engel et al., 1993; Kelm et
equivalent despite the negative influence normally al., 1994). In addition to its potential role as a mediator
provided by CD22 expression. These data collectively of intercellular interactions, the z140 amino acid cyto-
suggest that CD19 activates the CD22/SHP1 inhibitory plasmic domain of CD22 contains six tyrosines that are
pathway that then acts primarily on CD19. targets for rapid phosphorylation following surface Ig or
CD22 ligation (Wilson et al., 1991; Schulte et al., 1992).
Negative regulatory roles for CD22 in BCR signalingIntroduction
are proposed to be critical for normal B cell activation
(Cyster and Goodnow, 1997; Sato et al., 1998; Smith etB lymphocyte responses to transmembrane stimuli reg-
al., 1998), since immunoreceptor tyrosine-based inhibi-ulate development, negative selection in bone marrow,
tion motifs within CD22 recruit SHP1, a potent intracellu-activation, proliferation, and the generation of humoral
lar phosphatase with inhibitory functions (Doody et al.,responses in the periphery. The outcome of these re-
1995; Lankester et al., 1995; Law et al., 1996). Consistentsponses is determined in part by signal transduction
with a negative role for CD22, B cells from CD22-defi-through the B cell antigen receptor (BCR) complex. How-
cient (CD222/2) mice display augmented intracellularever, a context for BCR signal transduction is provided
Ca21 ([Ca21]i) responses after BCR ligation and exhibitby multiple intracellular signaling molecules and cell sur-
characteristics of chronic stimulation (O'Keefe et al.,face receptors that function as ªresponse regulatorsº
1996; Otipoby et al., 1996; Sato et al., 1996a; Nitschke(Healy and Goodnow, 1998; Tedder, 1998). Two of the
et al., 1997). By contrast, CD22 also associates withmajor response regulators on the surface of B cells are
ªpositiveº effector molecules (Law et al., 1996; TuscanoCD19, which forms a complex with the CD21 comple-
et al., 1996). This may explain why CD222/2 mice gener-ment receptor (Carroll, 1998; Fujimoto et al., 1998), and
ate reduced proliferative responses to BCR cross-link-CD22, a cell surface adhesion molecule (Tedder et al.,
ing (Otipoby et al., 1996; Sato et al., 1996a). Nonetheless,1997b). CD19 and CD22 may each associate directly
CD22 is a significant regulator of BCR signal trans-with cell-surface IgM (Leprince et al., 1993; Peaker and
duction.Neuberger, 1993; Carter et al., 1997).
The studies cited above suggest that CD19 and CD22CD19 is a 95,000 Mr glycoprotein expressed by early
reciprocally regulate BCR function. In addition, CD19pre-B cells from the time of immunoglobulin (Ig) heavy-
and CD22 have counterregulatory effects on mitogen-chain gene rearrangement until plasma cell differentia-
activated protein kinase activation (Tooze et al., 1997).tion. CD19 is a member of the Ig superfamily with an
In addition, Vav tyrosine phosphorylation is modest and
z240 amino acid cytoplasmic region containing nine
transient after BCR cross-linking in CD192/2 B cells,
tyrosine residues (Tedder and Isaacs, 1989), some of
yet uniquely augmented after BCR or CD19 ligation in
which are rapidly phosphorylated following BCR and/
CD222/2 B cells (Sato et al., 1997a). Alternatively how-
ever, CD19 and CD22 may reciprocally regulate each
other's functions and thereby regulate BCR signal trans-* To whom correspondence should be addressed (e-mail: thomas.
tedder@duke.edu). duction indirectly. In support of this hypothesis, CD19
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Figure 1. Regulatory Interactions between
CD19 and CD22 following BCR Ligation
(A) Decreased SHP1 association with phos-
phorylated CD22 in CD192/2 B cells. Purified
splenic B cells (107/lane) from CD192/2 and
wild-type mice were incubated with F(ab9)2
anti-IgM Abs for the times shown, detergent
lysed, and incubated with protein-G beads
and either anti-SHP1 Ab or control rabbit IgG
(CTL). Immunoprecipitated proteins were
subjected to SDS-PAGE and transferred onto
membranes for anti-phosphotyrosine (anti-
PTyr) immunoblotting. (B) CD19 tyrosine
phosphorylation in CD222/2 B cells. Purified
wild-type or CD222/2 splenic B cells (4 3 107/
lane) were incubated with anti-IgM before de-
tergent lysis. Cell lysates were incubated with
beads bearing either anti-CD19 or isotype-
matched control (CTL) mAb. Immunoprecipi-
tated proteins were analyzed by anti-PTyr
immunoblotting. (C) Protein tyrosine phosphor-
ylation in B cells from wild-type, CD192/2,
CD222/2, and CD19/CD222/2 mice following
BCR cross-linking. Purified splenic B cells (4 3
105/lane) incubated with either medium alone (time 0) or with anti-IgM for the indicated times were solubilized and subjected to SDS-
PAGE and subsequent anti-PTyr immunoblotting. Molecular weight standards (31023) are shown on the right. (D) Lyn and (E) Vav tyrosine
phosphorylation following BCR ligation in wild-type, CD192/2, CD222/2, and CD19/CD222/2 B cells. Lyn and Vav were immunoprecipitated
from cell lysates (107 cells/lane) and immunoblotted with anti-PTyr Ab (top panels). All blots were subsequently stripped and reprobed with
the specific Abs to verify loading equivalency (bottom panels). In (A±E), results are representative of those obtained with at least three sets
of mice. (F) Lyn kinase activity following BCR ligation. Splenic B cells (107) were solubilized before or after incubation with anti-IgM for 3 min,
followed by immunoprecipitation with anti-Lyn Ab or control rabbit IgG. Immunoprecipitates were then incubated with cdc2(6-20)NH2 peptide
and [g-32P] ATP. The radioactivity incorporated into cdc2 peptide was quantified by scintillation counting. Relative mean (6 SEM) kinase
activities are obtained from three experiments. Kinase activity is shown as percentage of wild-type B cells at 0 min, in which background and
unstimulated wild-type B cells were defined as 0% and 100%, respectively. Asterisks indicate sample means significantly different from wild-
type mice; p , 0.05.
expression is required for CD22 phosphorylation after phosphorylated CD22 was constitutively associated
with SHP1 in resting B cells (Figure 1A), and this associa-BCR ligation (Sato et al., 1997a). In the current biochemi-
cal studies, CD19 and CD22 were found to reciprocally tion increased after IgM ligation in wild-type and CD192/2
B cells. However, relatively little phosphoCD22 copre-modulate each other's functions. Moreover, the sup-
pressive influence of CD22 on B cell activation in vivo cipitated with SHP1 from resting and activated CD192/2
B cells when compared with wild-type B cells (Figurerequired CD19 expression. This suggests that, while
CD19 is necessary to initiate negative regulation pro- 1A). SHP1 phosphorylation was similar between wild-
type and CD192/2 B cells (data not shown). Thus, CD19vided by CD22 expression, CD19 is also likely to be a
major target of the CD22 inhibitory pathway. expression regulates SHP1 associations with CD22 be-
fore and after BCR ligation.
Results
CD19 Expression Regulates SHP1 Binding to CD22 CD22 Expression Regulates CD19
Tyrosine PhosphorylationSince CD19 expression is required for optimal CD22
phosphorylation after BCR ligation (Sato et al., 1997a), The effect of CD22 expression on CD19 tyrosine phos-
phorylation was assessed by immunoprecipitatingand phosphorylated CD22 binds SHP1 to mediate the
negative regulatory effects of CD22, regulatory interac- CD19 from CD222/2 and wild-type B cells before and
after BCR cross-linking. CD19 tyrosine phosphorylationtions between CD19, CD22, and SHP1 were assessed
further. SHP1 was immunoprecipitated from lysates of was constitutively higher in CD222/2 B cells and was
increased significantly after BCR ligation relative to wild-B cells from CD192/2 and wild-type mice before and
after BCR cross-linking. Immunoprecipitates were sub- type B cells (Figure 1B). Augmented CD19 tyrosine phos-
phorylation in CD222/2 B cells contrasts markedly withjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and then electrophoretic BCR phosphorylation, which is reduced in CD222/2 B
cells following BCR ligation (Sato et al., 1997a).transfer to nitrocellulose membranes. Anti-phosphoty-
rosine immunoblotting revealed the presence of a major We attempted to assess directly whether enhanced
CD19 phosphorylation in CD222/2 B cells resulted fromtyrosine phosphorylated protein that migrated at z140
kDa (Figure 1A). This protein was considered to be CD22 decreased SHP1 associations with CD22 using moth-
eaten-viable (Mev) mice. The Mev mutation results insince preclearance of the cell lysates with anti-CD22 Ab
depleted this band (data not shown). Similarly, this 140 functionally defective SHP1 protein (Kozlowski et al.,
1993). Heterozygous mev (mev/1) mice were used forkDa phosphoprotein band does not coprecipitate with
SHP1 in CD222/2 B cells (Sato et al., 1997a). Tyrosine these studies since the majority of their splenic B cells
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are conventional B cells, while splenocytes of homozy-
gous mev (mev/mev) mice are almost exclusively B1
(CD51) B cells. However, the results neither supported
nor contradicted the involvement of SHP1 in CD19 de-
phosphorylation. CD19 tyrosine phosphorylation tended
to be lower in B cells from mev/1 mice compared with
their wild-type littermates following BCR ligation (four
of six experiments; data not shown). By contrast, CD19
or BCR ligation induced normal [Ca21]i responses in
mev/1 B cells (data not shown). This contrasts with aug-
mented [Ca21]i responses by CD222/2 B cells after BCR
ligation (O'Keefe et al., 1996; Otipoby et al., 1996; Sato
et al., 1996a; Nitschke et al., 1997). In mev/mev B cells,
CD19 was not tyrosine phosphorylated at detectable
levels before or following BCR ligation (data not shown).
Furthermore, CD19 cross-linking failed to induce a mea-
surable [Ca21]i increase in mev/mev B cells. Analogously,
BCR ligation induces a reduced and blunted [Ca21]i re-
sponse in B1 cells (Krop et al., 1996). Thus, although
increased CD19 phosphorylation in CD222/2 B cells sug-
gests that CD19 is a target of the CD22/SHP1 complex,
this remains to be formally proven given the complex
Figure 2. Proliferation of CD19/CD222/2 B Cells in Response to Mi-phenotypes of mev mice.
togenic Signals
Spleen B cells (2 3 105/well) from wild-type, CD192/2, CD222/2,Tyrosine Phosphorylation in CD19/CD222/2 B Cells
and CD19/CD222/2 mice were purified with anti-Thy1.2 Ab-coated
To further dissect the relationships between CD19 and magnetic beads. B cells were cultured with the indicated concentra-
CD22 regulation of B cell function, CD19/CD222/2 mice tions of anti-IgM Abs, LPS, or anti-CD40 mAb. Proliferation was
were generated. The consequences of CD19 and CD22 assessed by the incorporation of labeled thymidine (1 mCi/well)
added during the last 16 hr of 72 hr cultures. Values represent theloss on signal transduction were evaluated by assessing
mean values (6 SEM) obtained from triplicate cultures. Mean valuestotal cellular protein tyrosine phosphorylation in purified
significantly different from wild-type proliferation levels are indi-B cells. Although some variation was observed between
cated, *p , 0.05. Results represent those obtained in four indepen-
B cells from individual mice in individual experiments, dent experiments.
overall levels of tyrosine phosphorylation in resting
splenic B cells were similar among all four mouse geno-
types: wild-type, CD192/2, CD222/2, and CD19/CD222/2. amplification of Lyn kinase activity (Fujimoto et al., 1999)
Resting B cells from CD192/2 mice had generally lower is critical for optimal CD22 phosphorylation. CD19 and
levels of endogenous protein tyrosine phosphorylation CD22 expression also reciprocally regulate Vav phos-
than resting B cells from wild-type mice in three of four phorylation (Sato et al., 1997a). In this study, Vav tyrosine
experiments, while protein phosphorylation in resting B phosphorylation was decreased in both CD192/2 and
cells from CD19/CD222/2 mice was always slightly CD19/CD222/2 B cells following BCR ligation, while Vav
higher than in wild-type B cells. Nonetheless, protein phosphorylation was increased in CD222/2 B cells (Fig-
phosphorylation in B cells from CD19/CD222/2 and ure 1E). Therefore, CD22 expression may negatively reg-
CD192/2 mice increased modestly, if at all, after BCR ulate either CD19 function or the Vav docking sites on
ligation (Figure 1C). By contrast, protein phosphoryla- phosphorylated CD19, or CD22 may regulate Vav phos-
tion increased in wild-type and CD222/2 B cells. Thus, phorylation directly.
BCR-induced tyrosine phosphorylation was severely im-
paired in CD19/CD222/2 and CD192/2 B cells, regardless Impaired B Cell Proliferation in CD19/CD222/2 Mice
of CD22 expression. The effects of CD19 and CD22 loss on B cell responses
to anti-IgM, lipopolysaccharide (LPS), and CD40 ligation
were assessed. In each case, proliferative responses byLyn and Vav Tyrosine Phosphorylation
in CD19/CD222/2 B Cells CD192/2 and CD19/CD222/2 B cells were remarkably
similar (Figure 2). Proliferation of CD19/CD222/2 andThe mechanism by which CD19 regulates CD22 phos-
phorylation was further assessed by identifying the sig- CD192/2 B cells was reduced in response to surface
IgM cross-linking (67 6 5% and 61 6 13% inhibition atnaling molecules affected by CD19 or CD22 loss. Since
impaired activation of Src-family PTKs is a hallmark of 20 mg/ml, respectively; p , 0.01 in four experiments
relative to wild-type B cells), LPS (30 6 10%; 32 6 3%B cells from CD192/2 mice (Fujimoto et al., 1999), Lyn
kinase activation was assessed. Lyn tyrosine phosphor- at 10 mg/ml, p , 0.05), and anti-CD40 Ab (75 6 5%; 71 6
9% at 10 mg/ml, p , 0.001). By contrast, proliferationylation was only modestly increased in CD192/2 and
CD19/CD222/2 B cells after BCR ligation (Figure 1D). of CD222/2 B cells was augmented or normal in response
to LPS or CD40 ligation as previously reported (SatoConsistent with modest increases in phosphorylation,
Lyn kinase activity in CD192/2 and CD19/CD222/2 B cells et al., 1996a). Although CD222/2 B cell proliferation in
response to IgM ligation was reduced (55 6 8% inhibi-was significantly lower than that in wild-type B cells
after BCR ligation (Figure 1F). This suggests that CD19 tion at 20 mg/ml, p , 0.01 in four experiments), the
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Figure 4. Humoral Immune Responses of CD19/CD222/2 Mice
Wild-type, CD192/2, CD222/2, and CD19/CD222/2 mice were in-
jected intraperitoneally with 100 mg of DNP-KLH in complete
Freund's adjuvant on days 0 and 21 (arrows) and bled at the indi-
cated times. Serum levels of anti-DNP Abs for three to six mice of
each genotype were determined by isotype-specific ELISA.
significantly lower than in wild-type mice (Figure 4).
CD222/2 mice generated higher IgM responses than
wild-type mice but similar IgG1 responses (Figure 4).
Similar results were obtained when the dilution of sera
giving half-maximal OD values (t-max1/2) in DNP-specific
ELISAs was determined by linear regression analysis.
Specifically, CD19/222/2 mice mounted primary IgM and
IgG1 responses that were only 26% and 6% of wild-type
responses (t-max1/2, 143 versus 542 for IgM; 212 versus
3,475 for IgG1) on day 7. IgM and IgG1 responses by
CD192/2 mice were 54% (294) and 10% (335) of wild-
type levels, while CD222/2 mice had increased IgM
(1,354) and wild-type IgG1 (3,076) responses. Secondary
IgM and IgG1 responses by CD19/222/2 and CD192/2
Figure 3. Serum Ig Levels mice on day 28 were reduced .95% compared to wild-
Values represent mean (6 SEM) Ig levels for 5±10 wild-type (gray type responses (IgM; wild-type 10,615, CD192/2 440,
histograms), CD192/2 (striped), CD222/2 (speckled), and CD19/
CD19/CD222/2 400) (IgG1; wild-type 113,806, CD192/2CD222/2 (filled) mice as determined by isotype-specific ELISA. Mean
565, CD19/CD222/2 942). CD222/2 mice had increasedvalues significantly different from wild-type levels are indicated; *p ,
IgM (13,286) and wild-type IgG1 (87,589) responses. Ger-0.05, ** p , 0.01.
minal centers were nearly absent in the spleens of CD19/
CD222/2 mice after secondary challenge as occurs incombined loss of CD19 and CD22 did not cause an
CD192/2 mice (Rickert et al., 1995; Sato et al., 1995).additive decrease in proliferation beyond the effect of
Thus, CD19 function dominates the role of CD22 duringCD19 loss alone (Figure 2).
humoral immune responses.
Humoral Immunity in CD19/CD222/2 Mice
Decreased Peripheral B CellsThe effects of combined CD19 and CD22 loss on serum
in CD19/CD222/2 MiceIg levels were assessed to determine the effect on B
Deletion of CD19 and/or CD22 from the cell surfacecell differentiation. Serum levels of most Ig isotypes
had only modest, if any, effects on the generation ofwere reduced significantly in both CD19/CD222/2 and
IgM2B220lo pro/pre-B cells, IgM1B220lo immature BCD192/2 mice when compared with wild-type mice (Fig-
cells, or IgM1B220hi mature B cells (Figure 5A; Table 1).ure 3). On average, IgM levels in CD19/CD222/2 mice
CD19/CD222/2 and CD222/2 mice had reduced numberswere reduced by 60%, IgG1 by 93%, IgG2a by 81%, IgG2b
of blood B cells, while circulating B cell numbers wereby 60%, and IgG3 by 60%. These were comparable to
fairly normal in CD192/2 mice (Figure 5B; Table 1). Similarthe decreases observed in CD192/2 mice: IgM reduced
to blood, CD19/CD222/2 mice had reduced numbers ofby 69%, IgG1 by 94%, IgG2a by 65%, IgG2b by 60%, and
peripheral lymph node B cells. Both CD19/CD222/2 andIgG3 by 41%. By contrast, CD222/2 mice had elevated
CD192/2 mice had significantly reduced numbers ofserum IgM levels (209% of wild-type levels, p , 0.005)
spleen B cells (40% and 44% reduction, respectivelybut normal levels of all IgG isotypes (Figure 3). Thus,
[Figure 5C; Table 1]). In most cases, reductions ob-the loss of CD22 did not significantly increase endoge-
served in CD222/2 mice were also evident in CD19/nous IgM levels in CD192/2 mice.
CD222/2 mice, and the loss of CD19 and CD22 hadThe influence of CD19 and CD22 loss on humoral
synergistic effects on peripheral B cell numbers.immune responses was assessed by immunizing mice
In contrast to what was observed for most peripheralwith the T cell-dependent antigen, 2,4-dinitrophenyl-
B cells, there was a significant reduction in the frequencykeyhole limpet hemocyanin (DNP-KLH). Following im-
of B2201IgM1 B cells in the peritoneal cavity of CD19/munization, primary and secondary IgM and IgG1 re-
sponses in CD19/CD222/2 and CD192/2 mice were CD222/2 and CD192/2 mice (Figure 5D; Table 1). This
Cross-Regulation of CD19 and CD22 Signaling
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Figure 5. Lymphocytes Present in Lymphoid
Tissues of CD19/CD222/2 Mice
Single cell suspensions of leukocytes were
isolated from wild-type, CD192/2, CD222/2,
and CD19/CD222/2 mice and examined by
two-color immunofluorescence staining with
flow cytometry analysis. Quadrant gates indi-
cate negative and positive populations of
cells as determined using isotype-matched
unreactive control mAbs. Horizontal dashed
lines in some histograms are provided for ref-
erence. The gated cell populations corre-
spond to the cells described in Table 1 and
are shown for reference. These results are
representative of those obtained with 6 or 7
two-month-old mice of each genotype.
primarily resulted from severely reduced numbers of Augmented but Delayed [Ca21]i Responses
in CD19/CD222/2 B CellsCD51B220lo B1 cells in these mice. This contrasted with
increased numbers of B1 cells in the peritoneum of Both CD19 and CD22 have hallmark effects on [Ca21]i
release following surface IgM cross-linking. CD192/2 BCD222/2 mice. Therefore, CD19 expression is required
for the generation and maintenance of B1 cells, which was cells generate near normal [Ca21]i responses with a de-
layed peak during the acute phase and a more prolongednot compensated for by the simultaneous loss of CD22.
late phase response (Sato et al., 1997b). By contrast,
CD22 loss results in dramatically increased levels ofSurface IgM Levels on CD19/CD222/2 B Cells
Although B cells mature normally in CD192/2 and [Ca21]i. Like CD222/2 B cells, CD19/CD222/2 B cells gen-
erated exaggerated [Ca21]i responses, although theseCD222/2 mice, altered surface IgM expression is a char-
acteristic feature of their B cells due to altered signaling responses also shared the characteristic features of
[Ca21]i responses in CD192/2 B cells (Figure 6). Similarthresholds. In the bone marrow of CD19/CD222/2 and
CD192/2 mice, IgM expression levels by B220loIgM1 im- results were obtained with optimal or suboptimal con-
centration of anti-IgM Abs. These results contrast mark-mature B cells were increased, while comparable B cells
in CD222/2 mice expressed wild-type IgM levels (Figure edly with all of the responses observed earlier where
CD192/2 and CD19/CD222/2 B cell responses were iden-5A; Table 1). IgM levels on mature B220hi B cells from
CD19/CD222/2 and CD222/2 mice were normal, while tical following BCR ligation. This suggests that, while
synergistic interactions between CD19 and CD22 influ-IgM levels on comparable B cells from CD192/2 mice
remained elevated. In blood, the cell-surface density of ence acute [Ca21]i flux, CD19 may not be a major target
of the CD22 inhibitory pathway in [Ca21]i regulation.IgM was also significantly elevated on B cells from
CD19/CD222/2 mice (Figure 5B; Table 1). However,
these IgM levels were intermediate between the mark-
edly increased levels on CD192/2 B cells and the signifi- Discussion
cantly decreased levels found on CD222/2 B cells. In
the spleen, surface IgM levels were reduced in CD19/ The current studies suggest that CD19 and CD22 regu-
late a common signaling pathway following BCR liga-CD222/2 and CD222/2 mice, while B cells from CD192/2
mice expressed wild-type IgM levels. In all cases, differ- tion. This provides a new model for how these two
cell-surface molecules cooperatively interact to regu-ences in cell size (light scatter properties) were not de-
tectable for CD192/2, CD222/2, or CD19/CD222/2 B cells late BCR signal transduction. Biochemical results from
CD192/2 and CD222/2 B cells show that both CD19 andwhen compared with comparable wild-type B cells
(data not shown). Therefore, IgM expression by CD19/ CD22 regulate tyrosine phosphorylation after BCR liga-
tion. In the absence of CD22 expression, CD19 wasCD222/2 B cells appeared to be synergistically regulated
by both CD19 and CD22 expression. tyrosine phosphorylated at much higher levels (Figure
Immunity
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Figure 6. Ca21 Responses following BCR Ligation in CD19/CD222/2
B Cells
Splenocytes from wild-type, CD192/2, CD222/2, and CD19/CD222/2
mice were loaded with indo-1 and stained with FITC-labeled anti-
B220 mAb. B cells were examined for relative [Ca21]i levels by flow
cytometry after gating on the B2201 population of cells. (A) Subopti-
mal or (B) optimal concentrations of Abs reactive with IgM were
added to the cell mixtures at the indicated times (arrows). An in-
crease in [Ca21]i over time is shown as an increase in the ratio of
indo-1 fluorescence. Values represent the ratios of fluorescence
intensity of cell populations after Ab treatment relative to the fluores-
cence intensity of untreated cells. These results are representative
of those obtained from five independent experiments.
1B). The significance of increased CD19 phosphoryla-
tion is underscored by the finding that both BCR phos-
phorylation and overall protein tyrosine phosphorylation
are reduced in CD222/2 B cells (Figure 1C; Sato et al.,
1997a). Reciprocally, CD22 is hypophosphorylated in
the absence of CD19 expression (Sato et al., 1997a), and
CD22/SHP1 complex formation was diminished (Figure
1A). CD19 expression is thereby likely to engage the
CD22/SHP1 inhibitory pathway that then appears to act
primarily on CD19. Therefore, CD19 and CD22 recipro-
cally influence the outcome of BCR engagement (Sato
et al., 1997a; Tooze et al., 1997), but these two receptors
may primarily modulate BCR-mediated signaling in an
interdependent fashion rather than independently.
Biochemical analysis of signaling in CD19/CD222/2
B cells further supports the idea that CD19 and CD22
primarily modulate BCR signaling in an interdependent
fashion. Mimicking CD192/2 B cells, overall tyrosine
phosphorylation was significantly decreased in CD19/
CD222/2 B cells after BCR ligation (Figure 1C). Further-
more, both Lyn activation and Vav phosphorylation in
CD19/CD222/2 B cells were reduced to the same extent
as was observed in CD192/2 B cells (Figures 1D±1F).
Since Lyn is considered to be the only tyrosine kinase
that can phosphorylate CD22 (Chan et al., 1998; Cornall
et al., 1998; Nishizumi et al., 1998; Smith et al., 1998),
decreased Lyn activation in CD192/2 and CD19/CD222/2
B cells (Figures 1D and 1F) is consistent with a model
in which CD19 directly regulates CD22 phosphorylation
before and after BCR ligation. Decreased CD22 phos-
phorylation in the absence of CD19 expression thereby
reduces SHP1 recruitment to the cell surface by phos-
phorylated CD22 (Figure 1A), the dominant binding part-
ner for SHP1 in B cells (Sato et al., 1997a). While it
is possible that a CD22/SHP1 complex reduces CD19
phosphorylation in wild-type B cells (Figure 1B) by
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regulating upstream PTK activity, wild-type levels of
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Lyn, Fyn, Blk, and Syk phosphorylation were found in may expedite efficient and rapid CD79a/b and Syk phos-
CD222/2 B cells (Figure 1D; Sato et al., 1997a). Thus, phorylation following BCR ligation, which may influence
CD19 may be a major target of the CD22/SHP1 inhibitory early phase [Ca21]i responses. The generation of wild-
pathway. Constitutive CD19 hyperphosphorylation may type [Ca21]i levels after BCR ligation in CD192/2 B cells
explain why B cells from CD222/2 mice exhibit pheno- is likely to result from a complex combination of positive
typic characteristics typical of chronically stimulated and negative factors including normal Syk activation but
cells (Sato et al., 1996b, 1997b) and why overall tyrosine decreased Lyn and CD22 phosphorylation (Fujimoto et
phosphorylation is reduced in CD222/2 B cells (Figure al., 1999). CD19 has also been suggested to regulate
1C; Sato et al., 1997a). B cells that overexpress CD19 PI-3 kinase activation (Buhl et al., 1997), which may
by 3-fold exhibit phenotypic characteristics similar to contribute to efficient [Ca21]i mobilization by generating
CD222/2 B cells and have similarly reduced protein tyro- phosphatidylinositol trisphosphate to recruit Btk to the
sine phosphorylation levels (M. F. and T. F. T., unpub- membrane (Buhl and Cambier, 1999). Nonetheless, the
lished data). Thus, constitutive CD19 hyperphosphoryla- need for CD19 expression to generate CD22/SHP1 com-
tion may chronically activate downstream signaling plexes at wild-type levels may explain why [Ca21]i re-
pathways that result in phenotypic changes and hypo- sponses are often sustained at high levels in CD192/2
phosphorylation of intracellular signaling molecules. B cells (Sato et al., 1997b). These results again suggest
Functional studies with B cells from CD19/CD222/2 complex and overlapping interactions between Lyn,
mice validate the hypothesis that CD19 expression is CD19, CD22, and SHP1 following BCR engagement, al-
necessary for CD22 function following BCR ligation. though CD19 and CD22 may modulate [Ca21]i mobiliza-
Rather than CD19 and CD22 deficiencies having addi- tion through independent mechanisms.
tive effects, CD19 deficiency was dominant. Mitogen- The reciprocal effects of CD19 and CD22 expression
induced proliferation of CD19/CD222/2 B cells was re- on the generation and/or maintenance of peritoneal B1
duced to levels identical with CD192/2 B cells (Figure cells are consistent with their reciprocal regulatory func-
2). Serum Ig levels in CD19/CD222/2 and CD192/2 mice tions. CD19/CD222/2 and CD192/2 mice shared an al-
were identical, despite increased IgM levels in CD222/2 most complete absence of peritoneal B1 cells (Figure
mice (Figure 3). Ab responses and germinal center for- 5D; Table 1). Reduced numbers of peritoneal B1 cells
mation in CD19/CD222/2 mice were identical to the mod- are a hallmark phenotype of CD192/2, Xid, and Vav2/2
est responses seen in CD192/2 mice, despite elevated mice, while CD222/2, motheaten, and Lyn2/2 mice share
IgM responses in CD222/2 mice (Figure 4). Spleen B increased numbers of B1 cells (reviewed in Tedder et
cell numbers in CD19/CD222/2 mice were reduced as al., 1997a). Notably, mice that overexpress CD19 also
in CD192/2 mice (Table 1). As occurs in CD192/2 mice, have increased numbers of peritoneal B1 cells (Sato et
B1 cells within the peritoneum of CD19/CD222/2 mice al., 1996b). This implies that CD19 hyperphosphorylation
were rare, despite increased B1 cell numbers in CD222/2 in CD222/2 mice (Figure 1B) may be responsible for the
mice (Figure 5; O'Keefe et al., 1996; Sato et al., 1996a). increase in B1 cell numbers. Regardless, the increase
It thus appears that CD22 expression does not influence in B1 cell numbers in CD222/2 mice required CD19 ex-
B cell responses to BCR engagement in the absence of pression.
CD19 expression. By contrast, CD19 and CD22 appear An unexpected finding was that CD22 and SHP1 were
to have overlapping influences on unactivated B cells, constitutively associated in wild-type B cells (Figure 1A).
particularly where a role for CD19 is absent or less pro- However, others have also reported this association in
nounced. For example, CD22 expression influenced cir- unstimulated splenocytes (Pani et al., 1997; Cornall et
culating B cell numbers with or without CD19 expression al., 1998; Smith et al., 1998). Constitutive SHP1 binding
(Table 1). While CD19 loss results in higher IgM expres- may be due to low-level CD22 tyrosine phosphorylation
sion by immature B cells and CD22 loss results in lower in resting primary B cells. Similarly, CD19/Lyn/Vav com-
IgM expression by more mature B cells, CD19/CD222/2
plexes are constitutively assembled in splenic B cells
B cells have high IgM expression early and low IgM
prior to BCR ligation (Fujimoto et al., 1999). It is not
expression later during maturation (Table 1). Thus, CD19
possible to discern whether CD22/SHP1 and CD19/Lyn/and CD22 are likely to have independent influences on
Vav complexes are present at low levels in all primaryB cells prior to BCR ligation, but following BCR ligation
B cells or whether they are present at higher levels in onlythe majority of CD22 function requires CD19 expression.
a subset of activated B cells. However, the constitutiveThe mechanisms through which CD19 and CD22 ex-
assembly of CD22/SHP1 and CD19/Lyn/Vav complexespression affect BCR-induced [Ca21]i mobilization are
in the majority of B cells would explain why the largelikely to be complex. [Ca21]i responses in CD19/CD222/2
majority of B cells in CD192/2, CD19-overexpressing, orB cells reflected the overlapping influences of CD19 and
CD222/2 mice exhibit characteristic phenotypic changesCD22 (Figure 6). Similar to CD222/2 B cells, augmented
(Tedder et al., 1997a, 1997b). Generally elevated or de-[Ca21]i responses are also a feature of Lyn2/2 and SHP-
creased surface IgM density by the majority of B cellsdefective B cells (Cyster and Goodnow, 1995; Chan et
is an example of this, as shown in Table 1 and Figure 5.al., 1998; Cornall et al., 1998; Nishizumi et al., 1998).
If CD19 and CD22 functions were only manifest followingThis suggests that the Lyn/CD22/SHP1 pathway plays
BCR engagement, then only a subpopulation of B cellsa critical role in downregulating [Ca21]i responses. How-
would be affected by the absence or overexpressionever, there is a delay in the initial phase of [Ca21]i re-
of CD19 and CD22. These observations suggest thatsponses in Lyn2/2 B cells (Chan et al., 1998; Cornall et
regulatory interactions between CD22/SHP1 and CD19/al., 1998), which also occurs in CD192/2 B cells (Sato et
Lyn/Vav complexes are likely to be dynamic compo-al., 1997b) and CD19/CD222/2 B cells (Figure 6). This
suggests that CD19 amplification of Lyn kinase activity nents of resting B cell homeostasis.
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shown on a 4-decade log scale. Fluorescence contours are shownAlthough CD19 and CD22 have both positive and neg-
as 50% log density plots. Positive and negative populations of cellsative effects on multiple signal transduction pathways,
were determined using unreactive isotype-matched Abs (Phar-the current study indicates that CD19 and CD22 benefit
Mingen) as controls for background staining.
from close functional interactions to regulate common
pathways. CD19 expression levels are tightly regulated Immunoprecipitation and Western Blotting
during B cell development (Krop et al., 1996; Sato et al., Splenic B cells were purified by removing T cells with anti-Thy1.2
Ab-coated magnetic beads (Dynal). Cells were stimulated with1997b), and CD19 overexpression dysregulates toler-
F(ab9)2 anti-mouse IgM Abs (40 mg/ml) and lysed in buffer containingance and results in autoantibody production (Sato et
1% Nonidet P-40, 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 1 mM Naal., 1996b; Inaoki et al., 1997). CD22 deficiency may
o-vanadate, 2 mM EDTA, 50 mM NaF, and protease inhibitors. Thealso contribute to autoimmunity (O'Keefe et al., 1999).
lysates were either analyzed by SDS-PAGE or subjected to immuno-
Similarly, Lyn has both positive and negative regulatory precipitation. For immunoprecipitations, the cell lysates were pre-
effects on BCR signaling (DeFranco et al., 1998), and cleared twice with rabbit IgG plus protein G-Sepharose beads (Phar-
macia Biotech), followed by incubation with protein G-beads plusLyn2/2 mice are autoimmune (Hibbs et al., 1995; Nishi-
specific Abs, or rabbit IgG (control) for 3 hr at 48C. CD19 was immu-zumi et al., 1995; Chan et al., 1997), which is partly
noprecipitated using Affigel 10 beads (Bio-Rad), bearing anti-CD19explained by a requirement for Lyn during CD22 and
mAb. After washing with the lysis buffer four times, immunoprecipi-FcgRII tyrosine phosphorylation (Chan et al., 1998; Nishi-
tates were subjected to SDS-PAGE and then electrophoretic transfer
zumi et al., 1998; Smith et al., 1998). FcgRII function to nitrocellulose membranes. Membranes were incubated with horse-
may also depend on CD19 regulation (Hippen et al., radish peroxidase-conjugated anti-phosphotyrosine Ab (4G10; Up-
state Biotechnology; PY99; Santa Cruz Biotechnology) and devel-1997). SHP1-defective B cells also have increased Src-
oped using an enhanced chemiluminescence kit (Pierce).family PTK activity (Lorenz et al., 1996; Siminovitch and
Neel, 1998), and these mice are autoimmune. Therefore,
In Vitro Lyn Kinase Assaytight regulation of CD19 function is likely to be a critical
After incubation of cell lysates with anti-Lyn Abs and protein-G
event for normal immunity since its expression modu- beads, the beads were subsequently washed four times in lysis
lates the activities of Src-family PTKs, CD22, SHP1, and buffer and twice in reaction buffer (50 mM Tris-HCl, pH 7.4, 10 mM
FcgRII. That CD19 is a major target of CD22 regulation MgCl2, 0.1 mM Na o-vanadate, and 1 mM DTT). The beads were
then incubated in 50 ml of reaction buffer containing 10 mg of cdc2(6-further emphasizes the necessity to closely control the
20)NH2 peptide (Upstate Biotechnology) and 10 mCi of [g-32P] ATPCD19 signaling pathway and amplification of Src-family
for 2 min at 258C. The reactions were terminated by adding 40%kinase activity. Alterations in CD19 and/or CD22 function
TCA and spotted onto p81 phosphocellulose paper. The phospho-
or expression could thereby contribute substantially to cellulose paper was washed five times with 0.75% phosphoric acid
autoimmunity or other diseases with modified B cell and once with acetone. Radioactivity was quantified by scintillation
function. counting.
B Cell ProliferationExperimental Procedures
Purified spleen B cells were cultured in 0.2 ml of culture medium in
96-well flat-bottom tissue culture plates with LPS (E. coli serotypeMice
0111:B4, Sigma), F(ab9)2 anti-mouse IgM Abs, or anti-CD40 mAbCD192/2 mice and CD222/2 mice were generated as described (En-
(1C10, generously provided by Dr. M. Howard, DNAX). Proliferationgel et al., 1995; Sato et al., 1996a). CD19/CD222/2 mice were gener-
was assessed by the incorporation of [3H]-labeled thymidine (1 mCi/ated through breedings of homozygous single-deficient mice. Lack
well) added during the last 16 hr of culture followed by scintillationof cell-surface CD19 and CD22 expression was verified by two-
counting. All treatments were carried out in triplicate cultures.color fluorescence cytometry. All mice used were 2±3 months of
age and were housed in a specific pathogen-free barrier facility.
Control age-matched wild-type mice were generated from heterozy- Mouse Immunization and Isotype-Specific ELISAs
gous breedings of CD191/2 3 CD221/2 mice. All studies and proce- Two month-old mice were immunized i.p. with 100 mg of DNP-
dures were approved by the Animal Care and Use Committee of KLH (Calbiochem-Novabiochem) in complete Freund's adjuvant and
Duke University. were boosted 21 days later. Mice were bled before and after immuni-
zation. ELISA assays were carried out as described previously (Engel
et al., 1995), using affinity purified mouse IgM, IgG1, IgG2a, IgG2b,Antibodies and Flow Cytometry
IgG3, and IgA (Southern Biotechnology Associates) to generate aThe mAbs used in this study included anti-CD19 (MB19-1; Sato
standard curve. The relative Ig concentration in individual sampleset al., 1996b), anti-CD22 (CY34.1, TIB163), biotinylated or FITC-
was calculated by comparing the mean OD obtained for triplicateconjugated anti-B220 (RA3-6B2), and phycoerythrin (PE)-conju-
wells to a semi-log standard curve of titrated standard Ab usinggated anti-CD5 (53-7.3, PharMingen). Antisera used included F(ab9)2
linear regression analysis. DNP-specific Ab titers of sera were mea-fragments of goat anti-mouse IgM (Cappel); anti-Lyn and anti-Vav
sured as above except that sample sera were added to ELISA plates(Santa Cruz Biotechnology); anti-SHP1 (Upstate Biotechnology) and
coated with DNP-bovine serum albumin (5 mg/ml, Calbiochem-anti-CD19 (generously provided by Dr. M. Grove, Duke University);
Novabiochem). Relative levels of hapten-specific IgM and IgG1 wereand biotinylated, FITC-conjugated, or alkaline phosphatase-conju-
determined for each group of mice using pooled serum samples.gated goat anti-mouse IgM, IgG, and IgA isotype-specific Abs
Sera were diluted at log intervals (1:10 to 1:106) and assessed for(Southern Biotechnology Associates). PE-conjugated Streptavidin
relative Ig levels as above except the results were plotted as OD(Fischer Scientific) was used to reveal biotin-coupled Ab staining.
versus dilution (log scale). The dilutions of sera giving half maximalSingle-cell suspensions were isolated from spleen, bone marrow,
OD values were determined by linear regression analysis, thus arbi-peripheral lymph nodes, and peritoneal cavity and counted using a
trary unit per ml values were generated for comparisons betweenhemocytometer prior to two-color immunofluorescence analysis.
sets of sera.Retroorbital venous plexus puncture was utilized to obtain blood.
Leukocytes (0.5±1 3 106) were stained at 48C using predetermined
optimal concentrations of Abs for 20 min as described (Zhou et al., Measurement of [Ca21]i
Spleen cells were loaded with 1 mM indo-1-AM ester (Molecular1994). Blood erythrocytes were lysed after staining using the Coulter
Whole Blood Immuno-Lyse kit. Cells with the forward and side light Probes) at 378C for 30 min. The cells were stained with FITC-conju-
gated anti-B220 Ab for 15 min at room temperature, washed, andscatter properties of mononuclear cells were analyzed on a FAC-
Scan flow cytometer (Becton Dickinson) with fluorescence intensity resuspended at 2 3 106 cells/ml. The ratio of fluorescence (525/405
Cross-Regulation of CD19 and CD22 Signaling
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nm) of B2201 cells was determined using a FACStar flow cytometer Engel, P., Zhou, L.-J., Ord, D.C., Sato, S., Koller, B., and Tedder,
T.F. (1995). Abnormal B lymphocyte development, activation and(Becton Dickinson). Baseline fluorescence ratios were collected for
1 min before F(ab9)2 anti-mouse IgM Abs (10 or 40 mg/ml) were differentiation in mice that lack or overexpress the CD19 signal
transduction molecule. Immunity 3, 39±50.added. Fluorescence ratios were collected at real time for 7 min.
Results were plotted as the fluorescence ratio at 20 sec intervals Fujimoto, M., Poe, J.C., Inaoki, M., and Tedder, T.F. (1998). CD19
with the background subtracted. An increase in the fluorescence regulates B lymphocyte responses to transmembrane signals.
ratio indicates an increase in [Ca21]i. Semin. Immunol. 10, 267±277.
Fujimoto, M., Poe, J.C., Jansen, P.J., Sato, S., and Tedder, T.F.
Statistical Analysis (1999). CD19 amplifies B lymphocyte signal transduction by regulat-
All data are shown as mean values 6 SEM. Comparisons between ing Src-family protein tyrosine kinase activation. J. Immunol. 162,
groups were made using the Student's t test. 7088±7094.
Healy, J.I., and Goodnow, C.C. (1998). Positive versus negative sig-
Acknowledgments naling by lymphocyte antigen receptors. Annu. Rev. Immunol. 16,
645±670.
We thank R. Burges for technical assistance, M. Howard and M. Hibbs, M.L., Tarlinton, D.M., Armes, J., Grail, D., Hodgson, G., Mag-
Grove for reagents, and G. Kelsoe for helpful discussions. This work litto, R., Stacker, S.A., and Dunn, A.R. (1995). Multiple defects in the
was supported by National Institutes of Health grants CA-81776, immune system of Lyn-deficient mice, culminating in autoimmune
CA-54464, and HL-50985. disease. Cell 83, 301±311.
Hippen, K.L., Buhl, A.M., D'Ambrosio, D., Nakamura, K., Persin,
Received April 6, 1999; revised May 26, 1999. C., and Cambier, J.C. (1997). FcgRIIB1 inhibition of BCR-mediated
phosphoinositide hydrolysis and Ca21 mobilization is integrated by
References CD19 dephosphorylation. Immunity 7, 49±58.
Inaoki, M., Sato, S., Weintraub, B.C., Goodnow, C.C., and Tedder,
Buhl, A.M., and Cambier, J.C. (1999). Phosphorylation of CD19 Y484 T.F. (1997). CD19-regulated signaling thresholds control peripheral
and Y515, and linked activation of phosphatidylinositol 3-kinase, are tolerance and autoantibody production in B lymphocytes. J. Exp.
required for B cell antigen receptor-mediated activation of Bruton's Med. 186, 1923±1931.
tyrosine kinase. J. Immunol. 162, 4438±4446.
Kelm, S., Pelz, A., Schauer, R., Filbin, M.T., Tang, S., de Bellard,
Buhl, A.M., Pleiman, C.M., Rickert, R.C., and Cambier, J.C. (1997). M.-E., Schnaar, R.L., Mahoney, J.A., Hartnell, A., Bradfield, P., et
Qualitative regulation of B cell antigen receptor signaling by CD19: al. (1994). Sialoadhesin, myelin-associated glycoprotein and CD22
selective requirement for PI3-kinase activation, inositol-1,4,5-tris- define a new family of sialic acid-dependent adhesion molecules of
phosphate production and Ca21 mobilization. J. Exp. Med. 186, the immunoglobulin superfamily. Curr. Biol. 4, 965±972.
1897±1910. Kozlowski, M., Mlinaric-Rascan, I., Feng, G.S., Shen, R., Pawson,
Carroll, M.C. (1998). CD21/CD35 in B cell activation. Semin. Immu- T., and Siminovitch, K.A. (1993). Expression and catalytic activity of
nol. 10, 279±286. the tyrosine phosphatase PTP1C is severely impaired in motheaten
and viable motheaten mice. J. Exp. Med. 178, 2157±2163.Carter, R.H., Doody, G.M., Bolen, J.B., and Fearon, D.T. (1997).
Membrane IgM-induced tyrosine phosphorylation of CD19 requires Krop, I., Shaffer, A.L., Fearon, D.T., and Schlissel, M.S. (1996). The
a CD19 domain that mediates association with components of the signaling activity of murine CD19 is regulated during B cell develop-
B cell antigen receptor complex. J. Immunol. 158, 3062±3069. ment. J. Immunol. 157, 48±56.
Chalupny, N.J., Kanner, S.B., Schieven, G.L., Wee, S., Gilliland, L.K., Lankester, A.C., van Schijndel, G.M., and van Lier, R.A. (1995). He-
Aruffo, A., and Ledbetter, J.A. (1993). Tyrosine phosphorylation of matopoietic cell phosphatase is recruited to CD22 following B cell
CD19 in pre-B and mature B cells. EMBO J. 12, 2691±2696. antigen receptor ligation. J. Biol. Chem. 270, 20305±20308.
Chan, V.W.F., Meng, F., Soriano, P., Defranco, A.L., and Lowell, C.A. Law, C.-L., Sidorenko, S.P., Chandran, K.A., Zhao, Z., Shen, S.-H.,
(1997). Characterization of the B lymphocyte populations in Lyn- Fischer, E.H., and Clark, E.A. (1996). CD22 associates with protein
deficient mice and the role of Lyn in signal initiation and down- tyrosine phosphatase 1C, Syk, and phospholipase C-g1 upon B cell
regulation. Immunity 7, 69±81. activation. J. Exp. Med. 183, 547±560.
Chan, V.W.F., Lowell, C.A., and DeFranco, A.L. (1998). Defective Leprince, C., Draves, K.E., Geahlen, R.L., Ledbetter, J.A., and Clark,
negative regulation of antigen receptor signaling in Lyn-deficient B E.A. (1993). CD22 associates with the human surface IgM-B cell
lymphocytes. Curr. Biol. 8, 545±553. antigen receptor complex. Proc. Natl. Acad. Sci. USA 90, 3236±3240.
Cornall, R.J., Cyster, J.G., Hibbs, M.L., Dunn, A.R., Otipoby, K.L., Li, X., Sandoval, D., Freeberg, L., and Carter, R.H. (1997). Role of
CD19 tyrosine 391 in synergistic activation of B lymphocytes byClark, E.A., and Goodnow, C.C. (1998). Polygenic autoimmune traits:
coligation of CD19 and membrane Ig. J. Immunol. 158, 5649±5657.Lyn, CD22, and SHP-1 are limiting elements of a biochemical path-
way regulating BCR signaling and selection. Immunity 8, 497±508. Lorenz, U., Ravichandran, K.S., Burakoff, S.J., and Neel, B.G. (1996).
Lack of SHPTP1 results in src-family kinase hyperactivation andCyster, J.G., and Goodnow, C.C. (1995). Protein tyrosine phospha-
thymocyte hyperresponsiveness. Proc. Natl. Acad. Sci. USA 93,tase 1C negatively regulates antigen receptor signaling in B lympho-
9624±9629.cytes and determines thresholds for negative selection. Immunity
2, 13±24. Nishizumi, H., Taniuchi, I., Yamanashi, Y., Kitamura, D., Ilic, D., Mori,
S., Watanabe, T., and Yamamoto, T. (1995). Impaired proliferationCyster, J.G., and Goodnow, C.C. (1997). Tuning antigen receptor
of peripheral B cells and indication of autoimmune disease in lyn-signaling by CD22: integrating cues from antigens and the microen-
deficient mice. Immunity 3, 549±560.vironment. Immunity 6, 509±517.
Nishizumi, H., Horikawa, K., Mlinaric-Rascan, I., and Yamamoto, T.DeFranco, A.L., Chan, V.W.F., and Lowell, C.A. (1998). Positive and
(1998). A double-edged kinase Lyn: a positive and negative regulatornegative roles of the tyrosine kinase Lyn in B cell function. Semin.
for antigen receptor-mediated signals. J. Exp. Med. 187, 1343±1348.Immunol. 10, 299±308.
Nitschke, L., Carsetti, R., Ocker, B., Kohler, G., and Lamers, M.C.Doody, G.M., Justement, L.B., Delibrias, C.C., Mathews, R.J., Lin,
(1997). CD22 is a negative regulator of B-cell receptor signaling.J., Thomas, M.L., and Fearon, D.T. (1995). A role in B cell activation
Curr. Biol. 7, 133±143.for CD22 and the protein tyrosine phosphatase SHP. Science 269,
242±244. O'Keefe, T.L., Williams, G.T., Davies, S.L., and Neuberger, M.S.
(1996). Hyperresponsive B cells in CD22-deficient mice. ScienceEngel, P., Nojima, Y., Rothstein, D., Zhou, L.-J., Wilson, G.L., Kehrl,
274, 798±801.J.H., and Tedder, T.F. (1993). The same epitope on CD22 of B lym-
phocytes mediates the adhesion of erythrocytes, T and B lympho- O'Keefe, T.L., Williams, G.T., Batista, F.D., and Neuberger, M.S.
(1999). Deficiency in CD22, a B cell-specific inhibitory receptor, iscytes, neutrophils and monocytes. J. Immunol. 150, 4719±4732.
Immunity
200
sufficient to predispose to development of high affinity autoantibod- Uckun, F.M., Burkhardt, A.L., Jarvis, L., Jun, X., Stealey, B., Dibirdik,
ies. J. Exp. Med. 189, 1307±1313. I., Myers, D.E., Tuel-Ahlgren, L., and Bolen, J.B. (1993). Signal trans-
duction through the CD19 receptor during discrete developmentalO'Rourke, L.M., Tooze, R., Turner, M., Sandoval, D.M., Carter, R.H.,
stages of human B-cell ontogeny. J. Biol. Chem. 268, 21172±21184.Tybulewicz, V.L.J., and Fearon, D.T. (1998). CD19 as a membrane-
anchored adaptor protein of B lymphocytes: costimulation of lipid Weng, W.K., Jarvis, L., and LeBien, T.W. (1994). Signaling through
and protein kinases by recruitment of Vav. Immunity 8, 635±645. CD19 activates vav/mitogen-activated protein kinase pathway and
induces formation of a CD19/vav/phosphatidylinositol 3-kinaseOtipoby, K.L., Andersson, K.B., Draves, K.E., Klaus, S.J., Farr, A.G.,
complex in human B cell precursors. J. Biol. Chem. 269, 32514±Kerner, J.D., Perlmutter, R.M., Law, C.-L., and Clark, E.A. (1996).
32521.CD22 regulates thymus-independent responses and the lifespan of
B cells. Nature 384, 634±637. Wilson, G.L., Fox, C.H., Fauci, A.S., and Kehrl, J.H. (1991). cDNA
cloning of the B cell membrane protein CD22: a mediator of B-BPani, G., Siminovitch, K.A., and Paige, C.J. (1997). The motheaten
cell interactions. J. Exp. Med. 173, 137±146.mutation rescues B cell signaling and development in CD45-defi-
cient mice. J. Exp. Med. 186, 581±588. Zhou, L.-J., Smith, H.M., Waldschmidt, T.J., Schwarting, R., Daley,
J., and Tedder, T.F. (1994). Tissue-specific expression of the humanPeaker, C.J.G., and Neuberger, M.S. (1993). Association of CD22
CD19 gene in transgenic mice inhibits antigen-independent B lym-with the B cell antigen receptor. Eur. J. Immunol. 23, 1358±1363.
phocyte development. Mol. Cell. Biol. 14, 3884±3894.Rickert, R.C., Rajewsky, K., and Roes, J. (1995). Impairment of T-cell-
dependent B-cell responses and B-1 cell development in CD19-
deficient mice. Nature 376, 352±355.
Sato, S., Steeber, D.A., and Tedder, T.F. (1995). The CD19 signal
transduction molecule is a response regulator of B-lymphocyte dif-
ferentiation. Proc. Natl. Acad. Sci. USA 92, 11558±11562.
Sato, S., Miller, A.S., Inaoki, M., Bock, C.B., Jansen, P.J., Tang,
M.L.K., and Tedder, T.F. (1996a). CD22 is both a positive and nega-
tive regulator of B lymphocyte antigen receptor signal transduction:
altered signaling in CD22-deficient mice. Immunity 5, 551±562.
Sato, S., Ono, N., Steeber, D.A., Pisetsky, D.S., and Tedder, T.F.
(1996b). CD19 regulates B lymphocyte signaling thresholds critical
for the development of B-1 lineage cells and autoimmunity. J. Immu-
nol. 157, 4371±4378.
Sato, S., Jansen, P.J., and Tedder, T.F. (1997a). CD19 and CD22
reciprocally regulate Vav tyrosine phosphorylation during B lympho-
cyte signaling. Proc. Natl. Acad. Sci. USA 94, 13158±13162.
Sato, S., Steeber, D.A., Jansen, P.J., and Tedder, T.F. (1997b). CD19
expression levels regulate B lymphocyte development: human CD19
restores normal function in mice lacking endogenous CD19. J. Im-
munol. 158, 4662±4669.
Sato, S., Tuscano, J.M., Inaoki, M., and Tedder, T.F. (1998). CD22
negatively and positively regulates signal transduction through the
B lymphocyte antigen receptor. Semin. Immunol. 10, 287±297.
Schulte, R.J., Campbell, M.A., Fischer, W.H., and Sefton, B.M. (1992).
Tyrosine phosphorylation of CD22 during B cell activation. Science
258, 1001±1004.
Siminovitch, K.A., and Neel, B.G. (1998). Regulation of B cell signal
transduction by SH2-containing protein-tyrosine phosphatases.
Semin. Immunol. 10, 329±347.
Smith, K.G.C., Tarlinton, D.M., Doody, G.M., Hibbs, M.L., and Fearon,
D.T. (1998). Inhibition of the B cell by CD22: a requirement for Lyn.
J. Exp. Med. 187, 807±811.
Tedder, T.F. (1998). Response-regulators of B lymphocyte signaling
thresholds provide a context for antigen receptor signal transduc-
tion. Semin. Immunol. 10, 259±265.
Tedder, T.F., and Isaacs, C.M. (1989). Isolation of cDNAs encoding
the CD19 antigen of human and mouse B lymphocytes: a new mem-
ber of the immunoglobulin superfamily. J. Immunol. 143, 712±717.
Tedder, T.F., Inaoki, M., and Sato, S. (1997a). The CD19/21 complex
regulates signal transduction thresholds governing humoral immu-
nity and autoimmunity. Immunity 6, 107±118.
Tedder, T.F., Tuscano, J., Sato, S., and Kehrl, J.H. (1997b). CD22,
a B lymphocyte-specific adhesion molecule that regulates antigen
receptor signaling. Annu. Rev. Immunol. 15, 481±504.
Tooze, R.M., Doody, G.M., and Fearon, D.T. (1997). Counterregula-
tion by the coreceptors CD19 and CD22 of MAP kinase activation
by membrane immunoglobulin. Immunity 7, 59±67.
Tuscano, J.M., Engel, P., Tedder, T.F., Agarwal, A., and Kehrl, J.H.
(1996). Involvement of p72syk kinase, p53/56lyn kinase and phos-
phatidyl inositol-3 kinase in signal transduction via the human B
lymphocyte antigen CD22. Eur. J. Immunol. 26, 1246±1252.
Tuveson, D.A., Carter, R.H., Soltoff, S.P., and Fearon, D.T. (1993).
CD19 of B cells as a surrogate kinase insert region to bind phosphati-
dylinositol 3-kinase. Science 260, 986±989.
